NEW YORK, NY / ACCESSWIRE / September 21, 2017 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, will present at this year's MicroCap Conference at 2:00 PM ET on October 5, 2017, in New York City. Chief Executive Officer Khoso Baluch will provide an overview of the company's business and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
CONFERENCE OVERVIEW AND STRUCTURE
The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.
The MicroCap Conference will take place in New York City at the Essex House on October 5th. Registration will begin on Thursday at 7:00 AM, and will last until the evening. These days will be jam-packed with company sessions, presentations, good food, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers - only portfolio managers, analysts, and private investors.
REGISTRATION FOR INVESTORS
To register, please go to our website (microcapconf.com/conferences/new-york-2-2017/), and click "Investor Registration".
PARTICIPATING COMPANIES
For our most updated list of companies, please go to our website (microcapconf.com/conferences/new-york-2-2017/).
News Compliments of ACCESSWIRE.
FOR MORE INFORMATION
Please visit: www.microcapconf.com
Or, contact Tony Yu at [email protected]
ABOUT CORMEDIX
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for 5 additional years of QIDP market exclusivity in the event of U.S. approval. Neutrolin is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes, and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. For more information, visit: www.cormedix.com.
CORMEDIX CONTACTS:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.: [email protected]; (212) 375-2664
Janine McCargo: [email protected]; (646) 604-5150
SOURCE: CorMedix Inc.